| Fluorescent sensors for measuring metal ions in living systems KP Carter, AM Young, AE Palmer Chemical reviews 114 (8), 4564-4601, 2014 | 2280 | 2014 |
| Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11 J Li, T Yakushi, F Parlati, AL Mackinnon, C Perez, Y Ma, KP Carter, ... Nature chemical biology 13 (5), 486-493, 2017 | 138 | 2017 |
| Thiolutin is a zinc chelator that inhibits the Rpn11 and other JAMM metalloproteases L Lauinger, J Li, A Shostak, IA Cemel, N Ha, Y Zhang, PE Merkl, ... Nature chemical biology 13 (7), 709-714, 2017 | 108 | 2017 |
| Discovery of a ZIP7 inhibitor from a Notch pathway screen E Nolin, S Gans, L Llamas, S Bandyopadhyay, SM Brittain, ... Nature chemical biology 15 (2), 179-188, 2019 | 59 | 2019 |
| Droplet microfluidic flow cytometer for sorting on transient cellular responses of genetically-encoded sensors BL Fiedler, S Van Buskirk, KP Carter, Y Qin, MC Carpenter, AE Palmer, ... Analytical chemistry 89 (1), 711-719, 2017 | 48 | 2017 |
| Critical comparison of FRET-sensor functionality in the cytosol and endoplasmic reticulum and implications for quantification of ions KP Carter, MC Carpenter, B Fiedler, R Jimenez, AE Palmer Analytical chemistry 89 (17), 9601-9608, 2017 | 33 | 2017 |
| Generation of recombinant hyperimmune globulins from diverse B-cell repertoires SM Keating, RA Mizrahi, MS Adams, MA Asensio, E Benzie, KP Carter, ... nature biotechnology 39 (8), 989-999, 2021 | 18 | 2021 |
| Stereocontrolled synthesis of 1, 3-diols from enones: cooperative Lewis base-mediated intramolecular carbonyl hydrosilylations C Medina, KP Carter, M Miller, TB Clark, GW O’Neil The Journal of Organic Chemistry 78 (18), 9093-9101, 2013 | 16 | 2013 |
| Direct conversion of β-hydroxyketones to cyclic disiloxanes GW O’Neil, MM Miller, KP Carter Organic letters 12 (22), 5350-5353, 2010 | 15 | 2010 |
| A masked-alkene metathesis-based synthesis of isopulo’upone KP Carter, DJ Moser, JM Storvick, GW O’Neil Tetrahedron letters 52 (34), 4494-4496, 2011 | 13 | 2011 |
| Lack of blocking activity in anti-CTLA-4 antibodies reduces toxicity, but not anti-tumor efficacy EL Stone, KP Carter, EK Wagner, MA Asensio, E Benzie, YY Chiang, ... BioRxiv, 2021.07. 12.452090, 2021 | 11 | 2021 |
| Affinity maturation of antibodies by combinatorial codon mutagenesis versus error-prone PCR JF Simons, YW Lim, KP Carter, EK Wagner, N Wayham, AS Adler, ... MAbs 12 (1), 1803646, 2020 | 11 | 2020 |
| Capturing and recreating diverse antibody repertoires as multivalent recombinant polyclonal antibody drugs SM Keating, RA Mizrahi, MS Adams, MA Asensio, E Benzie, KP Carter, ... bioRxiv, 2020.08. 05.232975, 2020 | 9 | 2020 |
| GMP manufacturing and IND-enabling studies of a recombinant hyperimmune globulin targeting SARS-CoV-2 RA Mizrahi, WY Lin, A Gras, AR Niedecken, EK Wagner, SM Keating, ... Pathogens 11 (7), 806, 2022 | 5 | 2022 |
| Zinc: fluorescent sensors AE Palmer, JG Miranda, KP Carter Encyclopedia of Inorganic and Bioinorganic Chemistry, 1-14, 2011 | 4 | 2011 |
| Novel nucleic acid-guided nucleases DS Johnson, JF Simons, YW Lim, MJ Spindler, KP Carter, SK Sandhu, ... US Patent App. 18/336,922, 2024 | | 2024 |
| 1380 Non-clinical results and design of first-in-human study for GIGA-564, a third-generation anti-CTLA-4 monoclonal antibody JM Redman, V Poon, A Niedecken, Y Chiang, R Deng, K Stadtmiller, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| Abstract A32: GIGA-564, a third generation anti-CTLA-4 with minimal ability to block CTLA-4 binding to B7 ligands, has enhanced efficacy but reduced toxicity compared to … EL Stone, KP Carter, EK Wagner, MA Asensio, E Benzie, YY Chiang, ... Cancer Immunology Research 10 (12_Supplement), A32-A32, 2022 | | 2022 |
| GIGA-564, a third generation anti-CTLA-4 with minimal ability to block CTLA-4 binding to B7 ligands, has enhanced efficacy but reduced toxicity compared to ipilimumab in pre … EL Stone, K Carter, E Wagner, M Asensio, E Benzie, Y Chiang, G Coles, ... JOURNAL FOR IMMUNOTHERAPY OF CANCER 10, A1443-A1443, 2022 | | 2022 |
| 1389 GIGA-564 a third generation anti CTLA 4 with minimal ability to block CTLA 4 binding to B7 ligands has enhanced efficacy but reduced toxicity compared to ipilimumab in … E Stone, K Carter, E Wagner, M Asensio, E Benzie, Y Chiang, G Coles, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
